Health Infrastructure is planning for the new RNA Research and Pilot Manufacturing Facility that will enable research, development and production of a broad spectrum of RNA technologies locally.

OVERVIEW

The new facility will conduct small-scale production of messenger RNA (mRNA), synthetic RNA (sRNA) and lipid nanoparticles (LNP) encapsulation at a scale which will enable clinical trials of new therapeutics.

Viruses, cancers, genetic diseases and many other health-related issues are potentially treatable with RNA technologies.

Similar in structure to DNA, RNA is a nucleic acid found in every cell of the body, which transmits genetic information between DNA and proteins to control the amount and type of protein made within a cell. RNA can also help to turn genes on and off, aid chemical reactions, regulate cell behaviour and inhibit other RNAs.

The NSW Government has committed $72.2 million to build the RNA Research and Pilot Manufacturing Facility, as part of a total $95.8 commitment for the facility.

A further $119 million has been announced over 10 years for RNA research and development initiatives.

BENEFITS

The project will:

• Be the first opportunity for RNA research and development to be tested and developed locally, across the broad spectrum of RNA technology, reducing Australia’s reliance on international supply
• Provide Australian patients with faster access to new and innovative RNA therapeutics to treat diseases such as cancer and rare genetic diseases
• Attract global industry investment to Australia, foster local jobs and skills and secure domestic-market access to future therapeutics
• Be central to NSW’s thriving RNA research and development ecosystem, surrounded by medical and research facilities, existing infrastructure, and world-leading RNA and cell and gene therapy expertise
• Boost innovation and technology in NSW, centralise RNA knowledge and expertise, create highly skilled jobs, and help NSW become a global leader in RNA research and production
• Capitalise on NSW’s competitive advantage by translating its strengths in research and development into a sustainable commercial pipeline of RNA therapeutics and products.